Search
Carbamazepine
go.drugbank.com/drugs/DB00564ApprovedInvestigationalIt was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.
Dupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigationalIt was first approved by the FDA in 2017. … [A180478] Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.
Rabeprazole
go.drugbank.com/drugs/DB01129ApprovedInvestigationalIt is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. … Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Ibrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalApril 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. … [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014.
Antihemophilic factor human
go.drugbank.com/drugs/DB13192ApprovedInvestigationalFactor VIII, but does not contain the B-domain, which has no known biological function and [DB11607], which is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared … The complex was developed by CSL Behring or Baxter Healthcare Corporation and approved in the 90s.
Mixtures: VONCENTO 1000 UI/ 2400 UIIcotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
Tranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalIt possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. … [L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Medium-chain triglycerides
go.drugbank.com/drugs/DB13959ApprovedInvestigationalMedium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms.
Ansuvimab
go.drugbank.com/drugs/DB16385ApprovedHowever, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB … [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.